Wilkins Investment Counsel Inc. Sells 13,983 Shares of Johnson & Johnson $JNJ

Key Points

• Wilkins Investment Counsel trimmed its Johnson & Johnson stake by 12.4%, selling 13,983 shares and leaving it with 98,950 shares (~$20.48M), about 3.0% of its portfolio and its 7th-largest holding.
• Company insiders sold a total of 30,142 J&J shares (~$7.36M) over the last quarter, including EVP Timothy Schmid (22,623 shares at $244.33) and EVP Vanessa Broadhurst (6,197 shares at $243.39); corporate insiders now own 0.16% of the stock.
• J&J beat Q1 estimates (EPS $2.70 vs. $2.68 est.; revenue $24.06B), set FY2026 guidance of $11.45–$11.65 EPS, and raised its quarterly dividend to $1.34 ($5.36 annualized, 2.4% yield; ex-dividend date May 26).

Wilkins Investment Counsel Inc. reduced its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 12.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 98,950 shares of the company's stock after selling 13,983 shares during the quarter. Johnson & Johnson accounts for approximately 3.0% of Wilkins Investment Counsel Inc.'s portfolio, making the stock its 7th largest holding. Wilkins Investment Counsel Inc.'s holdings in Johnson & Johnson were worth $20,478,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. AustralianSuper Pty Ltd raised its stake in Johnson & Johnson by 632.0% during the third quarter. AustralianSuper Pty Ltd now owns 89,183 shares of the company's stock worth $16,536,000 after purchasing an additional 77,000 shares during the period. J.W. Cole Advisors Inc. increased its position in shares of Johnson & Johnson by 2.2% in the third quarter. J.W. Cole Advisors Inc. now owns 130,934 shares of the company's stock worth $24,278,000 after acquiring an additional 2,769 shares in the last quarter. Guinness Asset Management LTD increased its position in shares of Johnson & Johnson by 0.4% in the third quarter. Guinness Asset Management LTD now owns 1,383,195 shares of the company's stock worth $251,216,000 after acquiring an additional 5,994 shares in the last quarter. Greenberg Financial Group acquired a new stake in shares of Johnson & Johnson in the fourth quarter worth $954,000. Finally, National Pension Service increased its position in shares of Johnson & Johnson by 3.2% in the third quarter. National Pension Service now owns 4,926,569 shares of the company's stock worth $913,484,000 after acquiring an additional 151,707 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Timothy Schmid sold 22,623 shares of the company's stock in a transaction on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the completion of the transaction, the executive vice president directly owned 26,769 shares in the company, valued at $6,540,469.77. This represents a 45.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Vanessa Broadhurst sold 6,197 shares of the company's stock in a transaction on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the transaction, the executive vice president owned 23,003 shares of the company's stock, valued at approximately $5,598,700.17. The trade was a 21.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 30,142 shares of company stock valued at $7,360,528. Corporate insiders own 0.16% of the company's stock.

Johnson & Johnson Stock Performance

JNJ stock opened at $225.59 on Wednesday. The company has a quick ratio of 0.77, a current ratio of 1.03 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $543.05 billion, a price-to-earnings ratio of 26.08, a P/E/G ratio of 2.20 and a beta of 0.27. Johnson & Johnson has a 12 month low of $146.12 and a 12 month high of $251.71. The firm has a 50 day moving average of $238.49 and a two-hundred day moving average of $220.15.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. The business had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. Johnson & Johnson's quarterly revenue was up 9.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, equities analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This represents a $5.36 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.30. Johnson & Johnson's dividend payout ratio is currently 60.12%.

Analysts Set New Price Targets

A number of research firms recently weighed in on JNJ. Bank of America raised their price target on shares of Johnson & Johnson from $253.00 to $254.00 and gave the company a "neutral" rating in a report on Wednesday, April 15th. Freedom Capital downgraded shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research report on Friday, January 16th. Rothschild & Co Redburn raised their price target on shares of Johnson & Johnson from $180.00 to $210.00 and gave the stock a "neutral" rating in a research report on Thursday, February 19th. Wall Street Zen downgraded shares of Johnson & Johnson from a "buy" rating to a "hold" rating in a research report on Saturday, February 14th. Finally, Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $220.00 to $250.00 and gave the company a "hold" rating in a research note on Wednesday, April 15th. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of "Moderate Buy" and an average target price of $252.48.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company's pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.